An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: James L Januzzi, Joseph Garasic, Scott Kasner, Vickie McDonald, Mark C Petrie, Jonathan Seltzer, Michael J. Mauro, Kevin Croce, Ellin Berman, Michael W.N. Deininger, Andreas Hochhaus, Javier Pinilla-Ibarz, Franck E. Nicolini, Dong-Wook Kim, Daniel J. DeAngelo, Hagop M. Kantarjian, Jing Xu, Shouryadeep Srivastava, Daniel Naranjo, Jorge E. Cortes
Institutions: Massachusetts General Hospital, University of Pennsylvania, Barts Health NHS Trust, University of Glasgow, Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital, Harvard University, Huntsman Cancer Institute, Jena University Hospital, Moffitt Cancer Center, Hôpital Lyon Sud, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Takeda Oncology (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3030016907